Guide
Microdose vs Standard Tirzepatide: The Price Gap and the Evidence Gap
Microdose programmes are about $39 a month cheaper on captured figures — $1,764 a year against $2,232. They also use doses below every dose studied in SURMOUNT-1, so no p
Microdose programmes are about $39 a month cheaper on captured figures — $1,764 a year against $2,232. They also use doses below every dose studied in SURMOUNT-1, so no published efficacy figure applies to them at any price.
What does the comparison actually show?
| Term | Microdose | Standard |
|---|---|---|
| Month-to-month | $189 | $215 |
| 3-month | $159 | $195 |
| 6-month | $150 | $190 |
| 12-month | $147 | $186 |
| Twelve-month total | $1,764 | $2,232 |
| Trial evidence at this dose | None | 22.5% at 15 mg (SURMOUNT-1) |
Ranked on price alone, a microdose programme wins every table it appears in. That is exactly why we report the protocols separately: a microdose figure and a standard figure are not comparable, and a comparison site that sorts them together produces a ranking that is arithmetically correct and practically misleading.
“Microdose” is a marketing word rather than a defined quantity. Ask any provider for the figure in milligrams, and ask what clinical rationale applies to you specifically — since 2025 the surviving compounding route requires a prescriber to document one.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What does each route cost?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings card | $25 | $300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Compounded, 12-month, flat | $186 | $2,232 | Captured at source |
| Compounded, month-to-month, flat | $215 | $2,580 | Captured at source |
| Brand Zepbound, LillyDirect vials | $299–$449 | $4,788 | Captured at source |
| Brand Zepbound, retail pens | ~$1,060 | ~$12,720 | Third-party claim |
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is microdosing tirzepatide cheaper?
By about $39 a month on captured figures — $1,764 a year against $2,232 for the standard protocol.
Does microdosing tirzepatide work?
No published trial has tested it at those doses. SURMOUNT-1 studied 2.5 to 15 mg, above the microdose range, so its results do not describe what a microdose delivers.
What counts as a microdose?
There is no defined quantity — it is a marketing term for amounts below the approved starting dose. Ask for the figure in milligrams.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
- Microdose Tirzepatide: The Evidence GapJournal
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- GLP-1 Tirzepatide Rank: Evidence, Prices, Providers & ToolsCore & Trust
- How Dose Escalation Changes Tirzepatide CostJournal
Related coverage
- Tirzepatide Membership Fees: When the Advertised Price Is Not the Price
- Microdose semaglutide: cost and evidence
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Tirzepatide Telehealth in Virginia
- Tirzepatide Telehealth in Washington
- Tirzepatide Telehealth in West Virginia
- Tirzepatide Telehealth in Wisconsin
- Tirzepatide Telehealth in Wyoming
GLP-1 Tirzepatide Rank. “Microdose vs Standard Tirzepatide: The Price Gap and the Evidence Gap.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-microdose-vs-standard-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.